Ophthotech (OPHT) Stock: Here’s What You Need To Know

Ophthotech Corporation (NASDAQ:OPHT) On Monday, Ophthotech stock tumbled lower by 86% after it announced that its phase 3 trial in patients with wet age-related macular degeneration (Wet AMD) failed to meet the primary endpoint of the study. The stock was slaughtered immediately, causing a lot of panic selling, but for good reason. The key thing … Read more

Tesaro (TSRO) Stock: Here’s What You Need To Know

TESARO Inc. (NASDAQ:TSRO) On Monday, Tesaro Stock closed higher by 18.79% after the company had announced over the weekend that its drug was successful in a clinical trial in patients with ovarian cancer. The results were outstanding, and a big reason why the stock closed higher for the day. What makes the results even more … Read more

Biotech Stock News (RVNC) (DNAI)

Revance Therapeutics (NASDAQ:RVNC) On Tuesday June 14, 2016 shares of Revance Therapeutics went down in after-hours trading by 24% after the company stated that it had failed to meet the primary endpoint of its phase 3 clinical trial. The phase 3 trial was testing patients with lateral catheral lines or Crows Feet. The trial used … Read more

Biotech Stock News (ATHX) (FLXN)

Athersys (NASDAQ:ATHX) In after-hours trade on February 18, 2016 shares of Athersys were up 21% after the company announced that it had obtained positive phase 2 results for its stroke trial. The phase 2 trial was broken down into two different parts. The first part was a dose selection phase of 16 patients split into … Read more

Biotech Stock News (AMGN) (RGLS) (BIIB) (RVNC) (AGN)

Amgen, Inc. (NASDAQ:AMGN) On October 28, 2015 Amgen had announced that it had received FDA approval for its skin cancer drug known as IMLYGIC. This drug is an injection type drug that helps boost the immune system to fight off and kill cancerous skin cells. This therapy only treats Melanoma — skin cancer– but does … Read more

Biotech Stock News (BLUE) (SNTA) (MACK) (BXLT)

Bluebird Bio (NASDAQ:BLUE)  On October 19, 2015 shares of Bluebird Bio fell approximately 4% after the company announced that one patient on its old generation gene therapy had required two blood transfusions due to anemia. One thing to keep in mind was that this patient was blood transfusion free for 7 years and that’s why … Read more

Biotech Stock News (ONCE) (AAVL) (CLDN) (ADXS) (OPK) (PFE)

Spark Therapeutics (NASDAQ:ONCE) On October 5, 2015 shares of Spark Therapeutics ended the day up at least 25% after the company announced that it had achieved positive phase 3 results in patients with a rare form of blindness. This rare form of blindness stems from a mutation in the RPE65 gene of the eye which … Read more

Biotech Stock News (RPTP) (AERI) (CANF)

Raptor Pharmaceuticals (NASDAQ:RPTP) On Monday September 14, 2015 shares of Raptor Pharmaceuticals ended the day down 38% after the company announced that it had failed a phase 2b liver study in children with NASH — non-alcoholic steatohepatitis. The phase 2b trial enrolled up to 169 children with NASH between the ages of eight and seventeen. … Read more

Biotech Stock News (INO) (TTPH) (AKBA)

Inovio Pharmaceuticals (NASDAQ:INO)  On September 8, 2015 Inovio announced that it had dosed its first patient with its Universal HIV vaccine known as PennVax-GP. This trial is being run as a phase 1 trial that will assess the safety and tolerability of the vaccine in these patients with HIV. Although the phase 1 trial primarily … Read more

Biotech Stock News (RXII) (REGN) (SURG) (VRX) (ACAD)

Rxi Pharmaceuticals (NASDAQ:RXII) On August 31, 2015 Rxi announced that the 30-day review period for its IND of RXI-109 for scarring of macular degeneration has passed its review period and the IND is now active. The whole point of the 30-day review period is for the FDA to look at pre-clinical data and conclude whether … Read more